Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Tjan-Heijnen VCG, van Hellemond IEG, Peer PGM, Swinkels ACP, Smorenburg CH, van der Sangen MJC, Kroep JR, De Graaf H, Honkoop AH, Erdkamp FLG, van den Berkmortel FWPJ, de Boer M, de Roos WK, Linn SC, Imholz ALT, Seynaeve CM; Dutch Breast Cancer Research Group (BOOG) for the DATA Investigators. Tjan-Heijnen VCG, et al. Among authors: erdkamp flg. Lancet Oncol. 2017 Nov;18(11):1502-1511. doi: 10.1016/S1470-2045(17)30600-9. Epub 2017 Oct 12. Lancet Oncol. 2017. PMID: 29031778 Clinical Trial.
Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study.
Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Akkermans-Vogelaar JM, Punt CJ. Koopman M, et al. Ann Oncol. 2006 Oct;17(10):1523-8. doi: 10.1093/annonc/mdl179. Epub 2006 Jul 27. Ann Oncol. 2006. PMID: 16873425 Free article. Clinical Trial.
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.
Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJ, van Bochove A, Sinnige HA, Creemers GM, Tesselaar ME, Slee PHTJ, Werter MJ, Mol L, Dalesio O, Punt CJ. Koopman M, et al. Lancet. 2007 Jul 14;370(9582):135-142. doi: 10.1016/S0140-6736(07)61086-1. Lancet. 2007. PMID: 17630036 Clinical Trial.
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.
Tol J, Koopman M, Rodenburg CJ, Cats A, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, Mol L, Antonini NF, Punt CJ. Tol J, et al. Ann Oncol. 2008 Apr;19(4):734-8. doi: 10.1093/annonc/mdm607. Epub 2008 Feb 13. Ann Oncol. 2008. PMID: 18272912 Free article. Clinical Trial.
Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.
van Nes JG, Seynaeve C, Maartense E, Roumen RM, de Jong RS, Beex LV, Meershoek-Klein Kranenbarg WM, Putter H, Nortier JW, van de Velde CJ; Cooperating investigators of the Dutch TEAM trial. van Nes JG, et al. Ann Oncol. 2010 May;21(5):974-82. doi: 10.1093/annonc/mdp419. Epub 2009 Oct 29. Ann Oncol. 2010. PMID: 19875752 Free article. Clinical Trial.
Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial.
Hamberg P, Bos MM, Braun HJ, Stouthard JM, van Deijk GA, Erdkamp FL, van der Stelt-Frissen IN, Bontenbal M, Creemers GJ, Portielje JE, Pruijt JF, Loosveld OJ, Smit WM, Muller EW, Schmitz PI, Seynaeve C, Klijn JG; Dutch Breast Cancer Trialists' Group (BOOG). Hamberg P, et al. Clin Breast Cancer. 2011 Apr;11(2):103-13. doi: 10.1016/j.clbc.2011.03.003. Epub 2011 Apr 11. Clin Breast Cancer. 2011. PMID: 21569996 Clinical Trial.
Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy.
Lalisang RI, Erdkamp FL, Rodenburg CJ, Knibbeler-van Rossum CT, Nortier JW, van Bochove A, Slee PH, Voest EE, Wils JA, Wals J, Loosveld OJ, Smals AE, Blijham GH, Tjan-Heijnen VC, Schouten HC. Lalisang RI, et al. Breast Cancer Res Treat. 2011 Jul;128(2):437-45. doi: 10.1007/s10549-011-1558-3. Epub 2011 May 17. Breast Cancer Res Treat. 2011. PMID: 21584666 Clinical Trial.
Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.
Coombes RC, Bliss JM, Espie M, Erdkamp F, Wals J, Tres A, Marty M, Coleman RE, Tubiana-Mathieu N, den Boer MO, Wardley A, Kilburn LS, Cooper D, Thomas MW, Reise JA, Wilkinson K, Hupperets P. Coombes RC, et al. J Clin Oncol. 2011 Aug 20;29(24):3247-54. doi: 10.1200/JCO.2010.32.7254. Epub 2011 Jul 18. J Clin Oncol. 2011. PMID: 21768453 Clinical Trial.
A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study.
Reyners AKL, de Munck L, Erdkamp FLG, Smit WM, Hoekman K, Lalisang RI, de Graaf H, Wymenga ANM, Polee M, Hollema H, van Vugt MATM, Schaapveld M, Willemse PHB; DoCaCel Study Group. Reyners AKL, et al. Among authors: erdkamp flg. Ann Oncol. 2012 Nov;23(11):2896-2902. doi: 10.1093/annonc/mds107. Epub 2012 Jun 11. Ann Oncol. 2012. PMID: 22689176 Free article. Clinical Trial.
97 results